The technology under assessment is still in its early stage of development and evidence based answers to the AEs of SOC domain we selected during the protocol, cannot be given.
Lo Scalzo A et al. Result Card SOC3 In: Lo Scalzo A et al. Social aspects In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 2 December 2022]. Available from: http://corehta.info/ViewCover.aspx?id=267